Anlikang Meisuobamo Injection has obtained a drug registration certificate
August 1, 2025
Source: drugdu
65
On the evening of July 30th, Anglicorn announced that it had recently received a "Drug Registration Certificate" issued by the National Medical Products Administration for its injection of Metoprolol. According to the announcement information, this drug is mainly used for the treatment of acute skeletal muscle pain or discomfort symptoms, belonging to Class 3 chemical drugs, with a specification of 10ml: 1g, drug approval number H20254988, and an expiration date of July 28, 2030. According to relevant national policies and regulations, obtaining the Drug Registration Certificate this time is considered to have passed the consistency evaluation.
The company stated that obtaining the Drug Registration Certificate this time will further enrich its product pipeline. However, due to the particularity of the pharmaceutical industry, the sales of drugs will be affected by factors such as national policies and changes in the market environment, and there is significant uncertainty in the specific sales situation.
Source: Shanghai Securities Journal · China Securities Network
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Zhengda Tianqing targets 9.2 billion yuan drug September 18, 2025
- Announcement on the Holding Subsidiary Obtaining Medical Device Registration Certificate September 18, 2025
- Plans to invest RMB 42.74 million in Wuhan Huajiyuan to advance clinical trials of the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project September 18, 2025
- Eli Lilly wins again! Oral weight loss drug outperforms oral sirolimus in head-to-head tria September 18, 2025
- Hengrui’s breakthrough hepatitis B therapy arrives September 17, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
